Changes in Serum Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1–34)
- 1 July 2004
- journal article
- clinical trial
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 89 (7), 3332-3336
- https://doi.org/10.1210/jc.2003-032066
Abstract
Changes in biochemical markers of bone turnover following intermittent injections of human (h)PTH (1-34) suggest that bone formation is initially favored over bone resorption. hPTH (1-34) is also known to influence osteoclast maturation and activity through modulation of osteoblast-derived cytokines, such as receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), IL-6, and IL-6 soluble receptor (IL-6sR). In this experiment, we investigated the changes in serum levels of soluble RANKL (sRANKL), OPG, IL-6, and IL-6sR in patients with glucocorticoid-induced osteoporosis treated with hPTH (1-34). Fifty-one postmenopausal women with glucocorticoid-induced osteoporosis were randomized to receive 12 months of 400 U hPTH (1-34) ( approximately 40 microg) daily and standard hormone replacement therapy, or hormone replacement therapy alone. Serum levels of sRANKL, OPG, IL-6, and IL-6sR were measured at baseline, 1 month, and every 3 months thereafter for a total of 24 months. hPTH (1-34) caused a rapid and significant increase in sRANKL within 1 month, and the levels remained elevated throughout the duration of therapy. IL-6 and IL-6sR increased significantly within 1 month, but returned to baseline levels more rapidly. In contrast, OPG was mildly suppressed beginning 6 months after hPTH therapy. These data support the hypothesis that hPTH (1-34) initially stimulates osteoblast maturation and function, which in turn leads to osteoclast activation and a gradual rebalancing of bone formation and resorption.Keywords
This publication has 23 references indexed in Scilit:
- The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal OsteoporosisNew England Journal of Medicine, 2003
- Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormoneJournal of Cellular Biochemistry, 2003
- Parathyroid Hormone Stimulates Receptor Activator of NFκB Ligand and Inhibits Osteoprotegerin Expression via Protein Kinase A Activation of cAMP-response Element-binding ProteinJournal of Biological Chemistry, 2002
- In Vivo Demonstration that Human Parathyroid Hormone 1–38 Inhibits the Expression of Osteoprotegerin in Bone with the Kinetics of an Immediate Early GeneJournal of Bone and Mineral Research, 2000
- Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.JCI Insight, 1998
- Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoidsJournal of Endocrinology, 1998
- Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosisThe Lancet, 1997
- In vivo demonstration that parathyroid hormone and parathyroid hormone–related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factorJournal of Bone and Mineral Research, 1996
- Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption.JCI Insight, 1995
- Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cellsBiochemical and Biophysical Research Communications, 1991